Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Jamie Toombs is active.

Publication


Featured researches published by Jamie Toombs.


Neurology | 2016

Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia

Jonathan D. Rohrer; Ione O.C. Woollacott; Katrina M. Dick; Elizabeth Gordon; Alexander Fellows; Jamie Toombs; Ronald Druyeh; M. Jorge Cardoso; Sebastien Ourselin; Jennifer M. Nicholas; Niklas Norgren; Simon Mead; Ulf Andreasson; Kaj Blennow; Jonathan M. Schott; Nick C. Fox; Jason D. Warren; Henrik Zetterberg

Objective: To investigate serum neurofilament light chain (NfL) concentrations in frontotemporal dementia (FTD) and to see whether they are associated with the severity of disease. Methods: Serum samples were collected from 74 participants (34 with behavioral variant FTD [bvFTD], 3 with FTD and motor neuron disease and 37 with primary progressive aphasia [PPA]) and 28 healthy controls. Twenty-four of the FTD participants carried a pathogenic mutation in C9orf72 (9), microtubule-associated protein tau (MAPT; 11), or progranulin (GRN; 4). Serum NfL concentrations were determined with the NF-Light kit transferred onto the single-molecule array platform and compared between FTD and healthy controls and between the FTD clinical and genetic subtypes. We also assessed the relationship between NfL concentrations and measures of cognition and brain volume. Results: Serum NfL concentrations were higher in patients with FTD overall (mean 77.9 pg/mL [SD 51.3 pg/mL]) than controls (19.6 pg/mL [SD 8.2 pg/mL]; p < 0.001). Concentrations were also significantly higher in bvFTD (57.8 pg/mL [SD 33.1 pg/mL]) and both the semantic and nonfluent variants of PPA (95.9 and 82.5 pg/mL [SD 33.0 and 33.8 pg/mL], respectively) compared with controls and in semantic variant PPA compared with logopenic variant PPA. Concentrations were significantly higher than controls in both the C9orf72 and MAPT subgroups (79.2 and 40.5 pg/mL [SD 48.2 and 20.9 pg/mL], respectively) with a trend to a higher level in the GRN subgroup (138.5 pg/mL [SD 103.3 pg/mL). However, there was variability within all groups. Serum concentrations correlated particularly with frontal lobe atrophy rate (r = 0.53, p = 0.003). Conclusions: Increased serum NfL concentrations are seen in FTD but show wide variability within each clinical and genetic group. Higher concentrations may reflect the intensity of the disease in FTD and are associated with more rapid atrophy of the frontal lobes.


Molecular Biology and Evolution | 2014

Direct Estimates of Natural Selection in Iberia Indicate Calcium Absorption Was Not the Only Driver of Lactase Persistence in Europe

Oddný Ósk Sverrisdóttir; Adrian Timpson; Jamie Toombs; Cécile Lecoeur; Philippe Froguel; José Miguel Carretero; Juan Luis Arsuaga Ferreras; Anders Götherström; Mark G. Thomas

Lactase persistence (LP) is a genetically determined trait whereby the enzyme lactase is expressed throughout adult life. Lactase is necessary for the digestion of lactose--the main carbohydrate in milk--and its production is downregulated after the weaning period in most humans and all other mammals studied. Several sources of evidence indicate that LP has evolved independently, in different parts of the world over the last 10,000 years, and has been subject to strong natural selection in dairying populations. In Europeans, LP is strongly associated with, and probably caused by, a single C to T mutation 13,910 bp upstream of the lactase (LCT) gene (-13,910*T). Despite a considerable body of research, the reasons why LP should provide such a strong selective advantage remain poorly understood. In this study, we examine one of the most widely cited hypotheses for selection on LP--that fresh milk consumption supplemented the poor vitamin D and calcium status of northern Europes early farmers (the calcium assimilation hypothesis). We do this by testing for natural selection on -13,910*T using ancient DNA data from the skeletal remains of eight late Neolithic Iberian individuals, whom we would not expect to have poor vitamin D and calcium status because of relatively high incident UVB light levels. None of the eight samples successfully typed in the study had the derived T-allele. In addition, we reanalyze published data from French Neolithic remains to both test for population continuity and further examine the evolution of LP in the region. Using simulations that accommodate genetic drift, natural selection, uncertainty in calibrated radiocarbon dates, and sampling error, we find that natural selection is still required to explain the observed increase in allele frequency. We conclude that the calcium assimilation hypothesis is insufficient to explain the spread of LP in Europe.


Clinical Chemistry and Laboratory Medicine | 2013

Identification of an important potential confound in CSF AD studies: aliquot volume

Jamie Toombs; Ross W. Paterson; Michael P. Lunn; Jennifer M. Nicholas; Nick C. Fox; Chapman; Jonathan M. Schott; Henrik Zetterberg

Abstract Background: Cerebrospinal fluid (CSF) amyloid β1-42 (Aβ1-42), total tau (T-tau) and phosphorylated tau181 (P-tau) are finding increasing utility as biomarkers of Alzheimer’s disease (AD). The purpose of this study was to determine whether measured CSF biomarker concentrations were affected by aliquot storage volume and whether addition of detergent-containing buffer mitigates any observed effects. Methods: AD and control CSF was distributed into polypropylene tubes in aliquots of different volumes (50–1500 μL). Aβ1-42, T-tau and P-tau were measured with and without addition of Tween 20 (0.05%). Results: Measured concentrations of Aβ1-42 increased two-fold with aliquot storage volume. A volume increase of 10 µL caused an Aβ1-42 increase of 0.95 pg/mL [95% confidence interval (CI) 0.36–1.50, p=0.02] in controls, and 0.60 pg/mL (CI 0.23–0.98 pg/mL, p=0.003) in AD samples. Following addition of Tween 20, the positive relationship between Aβ1-42 and aliquot volume disappeared. T-tau and P-tau were not significantly affected. Conclusions: CSF aliquot storage volume has a significant impact on the measured concentration of Aβ1-42. The introduction of a buffer detergent at the initial aliquoting stage may be an effective solution to this problem.


Alzheimer's Research & Therapy | 2014

Amyloid-beta 42 adsorption following serial tube transfer

Jamie Toombs; Ross W. Paterson; Jonathan M. Schott; Henrik Zetterberg

IntroductionCerebrospinal fluid (CSF) amyloid-beta 38 (Aβ38), 40 (Aβ40), 42 (Aβ42) and total tau (T-tau) are finding increasing utility as biomarkers of Alzheimer’s disease (AD). The purpose of this study was to determine whether measured CSF biomarker concentrations were affected by transfer of CSF between tubes, and whether addition of a non-ionic surfactant mitigates any observed effects.MethodsAD and control CSF was transferred consecutively between polypropylene tubes. Aβ peptides and T-tau were measured with and without addition of Tween 20 (0.05%).ResultsMeasured concentrations of Aβ42 decreased by approximately 25% with each consecutive transfer. Measured concentrations of Aβ38 and Aβ40 were also observed to decrease significantly with each consecutive transfer (approximately 16% loss per transfer). Measured concentrations of T-tau also decreased significantly, but at much smaller magnitude than the Aβ peptides (approximately 4% loss per transfer). The addition of Tween 20 mitigated this effect in all samples.ConclusionsConsecutive CSF transfer between tubes has a significant impact on the measured concentration of all Aβ peptides, and significant effect of lesser magnitude on T-tau. This would be sufficient to alter biomarker ratios enough to mislead diagnosis. The introduction of Tween 20 at the initial aliquoting stage was observed to significantly mitigate this effect.


eLife | 2015

RIPOSTE: a framework for improving the design and analysis of laboratory-based research

Nicholas G. D. Masca; Elizabeth M. A. Hensor; Victoria Cornelius; Francesca M. Buffa; Helen M. Marriott; James Eales; Michael P. Messenger; Amy E. Anderson; Chris Boot; Catey Bunce; Robert Goldin; Jessica M Harris; Rod F Hinchliffe; Hiba Junaid; Shaun Kingston; Carmen Martin-Ruiz; Christopher P. Nelson; Janet Peacock; Paul Seed; Bethany Shinkins; Karl J. Staples; Jamie Toombs; Adam K.A. Wright; M. Dawn Teare

Lack of reproducibility is an ongoing problem in some areas of the biomedical sciences. Poor experimental design and a failure to engage with experienced statisticians at key stages in the design and analysis of experiments are two factors that contribute to this problem. The RIPOSTE (Reducing IrreProducibility in labOratory STudiEs) framework has been developed to support early and regular discussions between scientists and statisticians in order to improve the design, conduct and analysis of laboratory studies and, therefore, to reduce irreproducibility. This framework is intended for use during the early stages of a research project, when specific questions or hypotheses are proposed. The essential points within the framework are explained and illustrated using three examples (a medical equipment test, a macrophage study and a gene expression study). Sound study design minimises the possibility of bias being introduced into experiments and leads to higher quality research with more reproducible results. DOI: http://dx.doi.org/10.7554/eLife.05519.001


Scientific Reports | 2016

Amyloid precursor protein expression and processing are differentially regulated during cortical neuron differentiation

Petra Bergström; Lotta Agholme; Faisal Hayat Nazir; Tugce Munise Satir; Jamie Toombs; Henrietta Wellington; Joakim Strandberg; Thomas Olsson Bontell; Hlin Kvartsberg; Maria Holmström; Cecilia Boreström; Stina Simonsson; Tilo Kunath; Anders Lindahl; Kaj Blennow; Eric Hanse; Erik Portelius; Selina Wray; Henrik Zetterberg

Amyloid precursor protein (APP) and its cleavage product amyloid β (Aβ) have been thoroughly studied in Alzheimer’s disease. However, APP also appears to be important for neuronal development. Differentiation of induced pluripotent stem cells (iPSCs) towards cortical neurons enables in vitro mechanistic studies on human neuronal development. Here, we investigated expression and proteolytic processing of APP during differentiation of human iPSCs towards cortical neurons over a 100-day period. APP expression remained stable during neuronal differentiation, whereas APP processing changed. α-Cleaved soluble APP (sAPPα) was secreted early during differentiation, from neuronal progenitors, while β-cleaved soluble APP (sAPPβ) was first secreted after deep-layer neurons had formed. Short Aβ peptides, including Aβ1-15/16, peaked during the progenitor stage, while processing shifted towards longer peptides, such as Aβ1-40/42, when post-mitotic neurons appeared. This indicates that APP processing is regulated throughout differentiation of cortical neurons and that amyloidogenic APP processing, as reflected by Aβ1-40/42, is associated with mature neuronal phenotypes.


Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring | 2015

Do cerebrospinal fluid transfer methods affect measured amyloid β42, total tau, and phosphorylated tau in clinical practice?

Ross W. Paterson; Jamie Toombs; Miles D. Chapman; Jennifer M. Nicholas; Amanda Heslegrave; Catherine F. Slattery; Alexander J.M. Foulkes; Camilla N. Clark; Christopher A. Lane; Philip Sj. Weston; Michael P. Lunn; Nick C. Fox; Henrik Zetterberg; Jonathan M. Schott

Cerebrospinal fluid (CSF) neurodegenerative markers are measured clinically to support a diagnosis of Alzheimers disease. Several preanalytical factors may alter the CSF concentrations of amyloid β 1–42 (Aβ1–42) in particular with the potential to influence diagnosis. We aimed to determine whether routine handling of samples alters measured biomarker concentration compared with that of prompt delivery to the laboratory.


Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring | 2015

Using florbetapir positron emission tomography to explore cerebrospinal fluid cut points and gray zones in small sample sizes

Philip S.J. Weston; Ross W. Paterson; Marc Modat; Ninon Burgos; Manuel Jorge Cardoso; Nadia Magdalinou; Manja Lehmann; John Dickson; Anna Barnes; Irfan Kayani; David M. Cash; Sebastien Ourselin; Jamie Toombs; Michael P. Lunn; Catherine J. Mummery; Jason D. Warren; Nick C. Fox; Henrik Zetterberg; Jonathan M. Schott

We aimed to assess the feasibility of determining Alzheimers disease cerebrospinal fluid (CSF) cut points in small samples through comparison with amyloid positron emission tomography (PET).


Clinical Chemistry and Laboratory Medicine | 2015

The impact of Tween 20 on repeatability of amyloid β and tau measurements in cerebrospinal fluid.

Jamie Toombs; Ross W. Paterson; Jennifer M. Nicholas; Axel Petzold; Jonathan M. Schott; Henrik Zetterberg

*Corresponding author: Jamie Toombs, Institute of Neurology, Department of Molecular Neuroscience, University College London, London, UK, Phone: + 44 20 34483553, E-mail: [email protected] Ross W. Paterson and Jonathan M. Schott: Institute of Neurology, Department of Neurodegeneration, Dementia Research Centre, London, UK Jennifer M. Nicholas: Department of Medical Statistics, London; and School of Hygiene and Tropical Medicine, London, UK. http://orcid.org/0000-0001-6023-0391 Axel Petzold: Institute of Neurology, Department of Molecular Neuroscience, University College London, London, UK Henrik Zetterberg: Institute of Neurology, Department of Molecular Neuroscience, University College London, London, UK; Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden Letter to the Editor


Current Genetic Medicine Reports | 2015

Genetic Variants and Related Biomarkers in Sporadic Alzheimer's Disease

Rita Guerreiro; Jose Bras; Jamie Toombs; Amanda Heslegrave; John Hardy; Henrik Zetterberg

From a neuropathological perspective, elderly patients who die with a clinical diagnosis of sporadic Alzheimer’s disease (AD) are a heterogeneous group with several different pathologies contributing to the AD phenotype. This poses a challenge when searching for low effect size susceptibility genes for AD. Further, control groups may be contaminated by significant numbers of preclinical AD patients, which also reduces the power of genetic association studies. Here, we discuss how cerebrospinal fluid and imaging biomarkers can be used to increase the chance of finding novel susceptibility genes and as a means to study the functional consequences of risk alleles.

Collaboration


Dive into the Jamie Toombs's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Ross W. Paterson

UCL Institute of Neurology

View shared research outputs
Top Co-Authors

Avatar

Nick C. Fox

UCL Institute of Neurology

View shared research outputs
Top Co-Authors

Avatar

Michael P. Lunn

University College London

View shared research outputs
Top Co-Authors

Avatar

Amanda Heslegrave

UCL Institute of Neurology

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Kaj Blennow

Sahlgrenska University Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Nadia Magdalinou

UCL Institute of Neurology

View shared research outputs
Researchain Logo
Decentralizing Knowledge